Scientific Name: Tirzepatide
Manufacturer: Zhengzhou Pharmaceutical (ZPHC)
Form: 5 lyophilized vials × 7.5 mg each (total 37 mg)
Category: Metabolic & weight‑management research compound
Mechanism: Tirzepatide is a dual incretin agonist (GLP‑1 & GIP) that supports appetite suppression, improved insulin sensitivity, and enhanced weight‑loss outcomes.
⚗️ Storage & Handling
-
Store refrigerated at 2–8 °C (35–46 °F)
-
Protect from light; keep vials sealed until reconstitution
-
Maintain cold‑chain integrity during shipping
-
For research use only — not approved for human consumption outside supervised protocols
Parameter Standard Range Notes Total content 37.5 mg 5 vials × 7.5 mg Administration Subcutaneous injection Abdomen, thigh, or upper arm Frequency Weekly Long half‑life supports once‑weekly dosing Weekly dose 5–15 mg Escalated gradually in study protocols Timing Morning (fasted) Enhances appetite suppression and metabolic response Research focus Appetite suppression, insulin sensitivity, weight‑loss Dual incretin agonist
